Drug Type Allergen extract |
Synonyms- |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingClinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Intermittent asthma | Clinical | France | 01 Jan 2013 |
Phase 3 | 633 | 300IR 5-grass pollen sublingual tablet | adcuzqnsdq(dkdvyyijmo) = cczygzexjr hhhdjkeqtg (ankihvfdkm ) | - | 01 Feb 2017 | ||
Placebo | adcuzqnsdq(dkdvyyijmo) = ipuldjxtox hhhdjkeqtg (ankihvfdkm ) | ||||||
Not Applicable | 633 | 300IR sublingual tablet of 5-grass pollen allergen extract (4M) | lfjfhpgqhq(xxovzhotkz) = There were no reports of anaphylaxis zdanchploa (pazmmfgnqg ) View more | - | 01 Feb 2012 | ||
300IR sublingual tablet of 5-grass pollen allergen extract (2M) | |||||||
Not Applicable | Rhinoconjunctivitis IgE | IgG4 | 628 | Grass Allergen Tablets (100 IR) | uhdnzidklh(wukckbclxj) = ssljzwvhuv tbosvsjryv (jwtyyqjzfr ) View more | - | 01 Feb 2008 | |
Grass Allergen Tablets (300 IR) | uhdnzidklh(wukckbclxj) = cujxypnwgn tbosvsjryv (jwtyyqjzfr ) View more |